✅ Model Answer:
• Diagnosis: Factor XIII deficiency – normal PT/PTT with abnormal clot solubility test. Classic presentation: delayed umbilical stump bleeding and prolonged bleeding after circumcision.
• Any other test: Clot Solubility (5M Urea), Factor XIII assay (quantitative) to confirm deficiency; genetic testing (F13A1 or F13B gene).
• What to do next: Factor XIII concentrate (20-40 U/kg) or cryoprecipitate (1 unit/10 kg) for acute bleeding. For major surgery or prophylaxis, FXIII concentrate every 4-6 weeks.
• Follow-up plan: Prophylaxis with FXIII concentrate 20-40 U/kg every 4-6 weeks for severe deficiency to prevent intracranial hemorrhage. Monitor trough FXIII levels. Genetic counseling for family members.

✅ Model Answer:
• Genes:
- F13A1: encodes the A subunit (catalytic subunit). Located on chromosome 6 (6p24.2).
- F13B: encodes the B subunit (carrier subunit). Located on chromosome 1 (1q31-32.1).
• Inheritance: Autosomal recessive (both parents are carriers).
• Prevalence: Rare (1 in 1-2 million).
• Protein: Factor XIII is a transglutaminase that stabilizes fibrin clots by cross-linking fibrin strands.
• Pathophysiology: Deficiency leads to unstable clots that break down prematurely, causing delayed bleeding (rebleeding after initial hemostasis).

✅ Model Answer:
• Classic features:
- Delayed umbilical stump bleeding: Bleeding from the umbilical stump after the cord falls off (days to weeks after birth).
- Prolonged bleeding after circumcision: Delayed rebleeding.
- Soft tissue hematomas: Spontaneous or after minor trauma.
- Intracranial hemorrhage: Life-threatening, especially in infancy (most common cause of death).
- Joint bleeding: Less common than hemophilia.
- Poor wound healing: Wound dehiscence, scarring.
- Spontaneous abortions: In females (due to placental bleeding).
• Onset: Usually presents in infancy (umbilical stump bleeding) or early childhood.

✅ Model Answer:
• Screening tests:
- PT: Normal.
- PTT: Normal.
- Platelet count: Normal.
- Thrombin time: Normal.
• Specific tests:
- Clot solubility test: The most important screening test. A clot is placed in 5M urea or 1% monochloroacetic acid. In normal plasma, the clot remains intact for ≥24 hours. In FXIII deficiency, the clot dissolves within 1-2 hours.
- Factor XIII assay: Quantitative measurement of FXIII activity (normal >70%; severe deficiency <1%).
- Genetic testing: F13A1 or F13B gene mutations.
- Prenatal diagnosis: For families with known mutations.

✅ Model Answer:
• Acute bleeding:
- Factor XIII concentrate: 20-40 U/kg IV (preferred, when available).
- Cryoprecipitate: 1 unit per 10 kg body weight (contains FXIII, but less purified).
- Fresh frozen plasma (FFP): 15-20 mL/kg (contains FXIII, but large volume required).
• Prophylaxis:
- Factor XIII concentrate: 20-40 U/kg every 4-6 weeks (for severe deficiency or recurrent bleeding).
- Goal: Maintain trough FXIII levels >3-5% (to prevent spontaneous bleeding).
• Antifibrinolytics: Tranexamic acid can be used as adjunctive therapy for mucosal bleeding.
• Avoid: NSAIDs and aspirin.

✅ Model Answer:
• Intracranial hemorrhage: Most feared complication – can cause death or severe neurologic disability.
• Delayed wound healing: Poor scar formation, wound dehiscence.
• Recurrent soft tissue hematomas: Painful, may require surgical drainage.
• Spontaneous abortion: In pregnant females (due to placental abruption).
• Hemarthrosis: Less common than in hemophilia, but can occur.
• Alloimmunization: Development of inhibitors (antibodies) against FXIII (rare).
• Iron deficiency anemia: Due to chronic blood loss.

✅ Model Answer:
• Prognosis:
- Excellent with regular prophylaxis (FXIII concentrate every 4-6 weeks).
- Without prophylaxis: High risk of intracranial hemorrhage (30-50% mortality).
- Life expectancy: Normal with treatment.
- Morbidity: Mainly from intracranial hemorrhage and wound healing issues.
• Long-term follow-up:
- Regular FXIII trough levels: Maintain >3-5%.
- Neurologic monitoring: For early detection of intracranial bleeding.
- Prophylaxis: Lifelong (every 4-6 weeks).
- Genetic counseling: For family members (autosomal recessive, 25% recurrence).
- Pregnancy planning: Prophylaxis during pregnancy to prevent miscarriage.

✅ Model Answer:
• Clot solubility test: A qualitative screening test for factor XIII deficiency.
• Principle: Factor XIII cross-links fibrin strands, making the clot resistant to lysis. In the absence of FXIII, clots are unstable and dissolve in 5M urea or 1% monochloroacetic acid.
• Procedure:
1. A clot is formed from the patient's plasma (with calcium and thrombin).
2. The clot is placed in 5M urea at 37°C.
3. Normal clot remains intact for ≥24 hours.
4. In FXIII deficiency, the clot dissolves within 1-2 hours.
• Limitations:
- Not quantitative (cannot measure FXIII levels).
- Can be falsely normal in mild deficiency (FXIII >1-2%).
- Requires confirmatory FXIII assay.
• Clinical use: Suspicion of FXIII deficiency (delayed umbilical stump bleeding, normal PT/PTT).